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ABSTRACT 
Background: Practices of biopiracy to use genetic resources and indigenous knowledge by 
Western companies without benefit-sharing of those, who generated the traditional knowledge, 
can be understood as form of neocolonialism.  
Hypothesis: The One-World Medicine concept attempts to merge the best of traditional medicine 
from developing countries and conventional Western medicine for the sake of patients around the 
globe. 
Study design: Based on literature searches in several databases, a concept paper has been written.  
Legislative initiatives of the United Nations culminated in the Nagoya protocol aim to protect 
traditional knowledge and regulate benefit-sharing with indigenous communities. The European 
community adopted the Nagoya protocol, and the corresponding regulations will be implemented 
into national legislation among the member states. Despite pleasing progress, infrastructural 
problems of the health care systems in developing countries still remain. Current approaches to 
secure primary health care offer only fragmentary solutions at best. Conventional medicine from 
industrialized countries cannot be afforded by the impoverished population in the Third World. 
Confronted with exploding costs, even health systems in Western countries are endangered to 
burst. Complementary and alternative medicine (CAM) is popular among the general public in 
industrialized countries, although the efficacy is not sufficiently proven according to the 
standards of evidence-based medicine. CAM is often available without prescription as over-the-
counter products with non-calculated risks concerning erroneous self-medication and 
safety/toxicity issues. The concept of integrative medicine attempts to combine holistic CAM 
approaches with evidence-based principles of conventional medicine.  
Conclusion: To realize the concept of One-World Medicine, a number of standards have to be set 
to assure safety, efficacy and applicability of traditional medicine, e.g. sustainable production and 
quality control of herbal products, performance of placebo-controlled, double-blind, randomized 
clinical trials, phytovigilance, as well as education of health professionals and patients.  
 
Keywords: Complementary and alternative medicine; Evidence-based medicine; Integrative 
medicine; Nagoya protocol; Quality control; Traditional medicine 
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AYUSH, Department of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy; 
BCEA, Basic Conditions of Employment Act; CAM, Complementary and alternative medicine; 
CTMDR, Center for Traditional Medicine and Drug Research; GSP, Good Sourcing Practice; 
GAP, Good Agricultural Practice; GLP, Good Laboratory Practice; GMP, Good Manufacturing 
Practice; GCTP, Good Clinical trial Practice; KEMRI, Kenya Medical Research Institute; 
KNUST, Kwame Nkrumah University of Science and Technology; MCC, Medicines Control 
Council; NCCAM, National Center for Complementary and Alternative Medicine; NCCIH, 
National Center for Complementary and Integrative Health; NGO, non-governmental 
organization; NHIS, National Health Insurance Scheme; NNMDRA Nigeria Natural Medicine 
Development Agency; OTC, over the counter; THMP, traditional herbal medicinal product; 
TMMDA, Turkish Medicines and Medical Devises Agency; WHO, World Health Organization. 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
6 
 
1 Introduction 
This paper looks at the economic, legal and cultural underpinnings of biopiracy as both the 
historical and the contemporary practice. At the same time, it looks at current work in the life 
sciences, particularly in the field of pharmaceutical biology, in order to explore alternatives to 
biopiracy as a form of what Vandana Shiva has described as the plunder of knowledge (Shiva, 
1997).
 
 
Biopiracy is a term to blame the use of biological resources and knowledge of indigenous 
communities without sharing the venues generated by the economic exploitation of these 
resources and knowledge, respectively. There are a number of infamous examples of piracy 
related to nutritional or medicinal plants, e.g. basmati rice, Curcuma longa, Azadirachta indica, 
Harpagophytum procumbens, Commiphora mukul, Hoodia gordoni, Banisteriopsis caapi, 
Pelargonium reniforme and P. sidoides, Terminalia fernandiana and others. World Health 
Organization (WHO) and the United Nations Educational, Scientific, and Cultural Organization 
(UNESCO) draw international attention on the protection of indigenous knowledge in the context 
of intellectual property rights. The Declaration on the Rights of Indigenous People (UNDRIP) 
was launched by the UN General Assembly in 2007. The International Convention on Biological 
Diversity (CBD) aimed to protect rights of indigenous people sustainable uses of bioresources 
and conservation biodiversity achieved modest success, however, this treaty was not signed by 
several countries. Another important step in this development was the Nagoya Protocol on 
Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from Their 
Utilization to the Convention on Biological Diversity. The Nagoya Protocol contained rules to 
protect traditional medicinal knowledge and to compensate indigenous people for knowledge that 
is already being patented or being used in an inappropriate manner in the past (Efferth et al., 
2016). By creating incentives for the sustainable use of genetic resources, the Nagoya Protocol 
will not only foster research on genetic resources but will also contribute to the development of 
human well-being by utilization of biodiversity. The European Parliament accepted the protocol 
(EU, No 511/2014) on 16 April 2014. It entered into force on 12 October 2014. Main principles 
are (1) informed consent of the country of origin of the resource and (2) he mutually agreed terms 
between indigenous peoples and collaboration partner. 
To bring forward the implementation of the protocol, the Access and Benefit-Sharing 
Clearing-House (ABS Clearing-House) has been established. The task is to facilitate legal 
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transparency and monitor utilization of genetic resources. Most EU member states signed the 
Nagoya Protocol and expressed their commitment to ratify it. The ratification of the Nagoya 
Protocol by the EU does not automatically lead to ratification by all member states. The EU 
legislation only applies, where relevant national legislation exists in the countries, in which the 
relevant genetic resources and traditional knowledge are obtained. At the national level of each 
country, specific administrative or institutional circumstances might be considered for its 
effective implementation. 
Unless the ownership of indigenous knowledge is acknowledged, contemporary practices 
in the life sciences are still inclined regarding knowledge held by indigenous and local 
communities simply as raw material which, similarly to former colonialist models, are then used 
to manufacture goods produced in the West and with Western-based companies reaping the 
benefits from such industrial production (Efferth et al., 2016).  
Moreover, it can be argued that some practices in the life sciences, which have amounted 
to biopiracy may have caused scholars from humanities to be suspicious of the life sciences and 
their ethical standards in our globalized world as a whole. Yet, it is crucial to recall that forms of 
biopiracy are closely connected to the commercial business of multinational corporations such as 
Monsanto, a company which, starting in the 1990s, proceeded to patent life-forms and indigenous 
knowledge from a variety of different areas in what has been called the Global South. The 
economic use and increasing privatization of knowledge thus has to be separated from the 
academic field of the life sciences. Thus, it is inherently short-sighted to criticize a given 
academic discipline for the economic uses to which it is put. At the same time, it is nonetheless 
essential to investigate the entanglement of particular methods in the life sciences with forms of 
biopiracy.  
Finally, by bringing together cultural understandings of biopiracy with forms of 
contemporary practice in the life sciences, which have succeeded in steering clear of biopiracy by 
collaborating with local and indigenous communities, our paper is also meant to bridge the gap 
between the life sciences and the humanities with regard to biopiracy as a threat towards a 
globally shared, sustainable ownership of knowledge.  
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2 From colonialism to neocolonialism: Biopiracy 
2.1 Cultural approaches to biopiracy 
As a form of neocolonial exploitation of territories and people, biopiracy has been closely 
investigated by humanities. Its study has loomed large in fields such as postcolonial studies 
(Huggan and Tiffin, 2010), ecocriticism (Buell, 1995; Garrad, 2004), eco-feminism and material 
feminism (Kolodny, 1975; Shiva, 1997). Particularly in postcolonial studies, researchers have 
argued that the contemporary practice of biopiracy has to be seen in line with forms of neo-
colonialism. At present, they argue that the exploitation of nature and Third-World territories by 
colonial powers has been replaced by similar forms of exploitation at the hands of multinational 
corporations driven by shareholder-value in a neoliberal economic arena.  
 Even more disturbingly, many critics argue that the plunder of knowledge is inextricably 
linked to the emergence of life sciences disciplines such as botany in the 19
th
 century. Crucially, 
these approaches point to the entanglement between colonialism as a political and economic 
system on the one hand and the history of science on the other hand. These critics suggest that the 
emergence of empirical research and scientific disciplines such as botany was itself made 
possible and predicated upon colonial power structures and the related expropriation of natural 
resources (De Loughrey and Handley, 2011).
 
At worst, the life sciences may become a hand-
maiden of global corporations: life sciences research may discover the potency of indigenous and 
local forms of knowledge, which then provide the basis for the patenting of this knowledge by 
multinational companies, which continue to be based in the West. Scientific research may hence 
come to be appropriated by multinational companies in their quest for alternative and highly 
profitable forms of knowledge and find itself in an ethically undesirable moral complicity. This 
may be particularly true in the field of alternative and complementary medicine: as Western 
medicine increasingly acknowledges its limits, particularly in fields such as cancer research, the 
search for alternative medical knowledge increases. Yet, this search may in some contexts come 
to be inseparable from the financial benefits to be reaped from such newly-discovered 
knowledge.  
 
2.2 The legal underpinnings of biopiracy 
The charge of biopiracy is inextricably intertwined with notions of epistemology on the one hand 
and legal notions of intellectual property on the other hand. Epistemology denotes forms of 
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knowing, which are in their turn connected to forms and concepts of explanatory power, which 
often leads to concepts of ownership, e.g. in processes of patenting. Thus, historically, indigenous 
communities from across the globe – from Native Americans in the US to Maori in New Zealand 
and Aborigines in Australia – have held the notion that land cannot be owned. Their sense that 
neither land nor nature could be anyone’s property, but needed to be cherished and sustained led 
to colonial practices of what legal scholar Lindsay Robertson has called conquest by law. Thus, 
the epistemologies of indigenous communities and settler communities were fundamentally at 
odds with one another, and they proved to be mutually exclusive. The act of conquest thus also 
implied that one epistemological framework assumed precedence over another. The Western 
notion of land as something which could be owned, something which could become property, 
overrode indigenous concepts of the land, which held such ownership to be impossible. The law, 
in turn, cemented Western concepts in a way that their assumed superiority was then reframed 
not only as intellectually or culturally superior, but as legal. Epistemology and law are – 
especially if routed in the tradition of Roman law - inseparable in this context.  
What historically applied to differing epistemological notions of the land also held true 
for different definitions of nature. Here, too, local and indigenous communities held that nature 
could not be owned, nor could it consequently be patented. Local and indigenous knowledge of 
the medicinal power of plants, for instance, was recorded in documents which, in Western 
categories, could not be clearly classified. Thus, the Indian epic of the Bhagavad Gita recorded 
the use of turmeric and its anti-inflammatory medicinal properties; yet, the Bhagavad Gita was 
seen as a text which linked cultural, legal, social and medical forms of knowledge. As a hybrid 
text which was unclassifiable in the sense of Western systems of classification, the Bhagavad 
Gita hence held little value as a document with which Indian ownership of knowledge with 
regard to spices such as turmeric could be proved. It was this incompatibility of epistemologies 
and of traditions of knowledge transfer, which could serve as proof of ownership and of 
intellectual property rights which made the court decisions of the 1980s possible, which found in 
favor of the defendant (e.g. Monsanto) and against the plaintiff (e.g. the government of India).
 It is equally significant, however, that more recent court cases reversed this legislation. 
What is significant here is that there may also have been a shift in the acknowledgment of non-
Western epistemologies as forms of knowledge in their own right. Crucially, the beginning of the 
21
st
 century can thus not only be seen as an age of apology (Gibney et al., 2008), in which a 
number of Western governments apologized for the wrongs they had inflicted on their indigenous 
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populations in Australia, Canada or New Zealand, but also as the reversal of patent cases, which 
were now acknowledged to be severe infringements of the rights of indigenous communities. It is 
interesting to look at these court cases in some more detail for the following reasons. First, they 
illustrate, in the language of the court, the practices leading to the patenting of the medicinal 
power of plants by Western corporations or Western scientists working for pharmaceutical 
companies. Second, they address the relationship between bioprospecting and biopiracy. Third, 
they point to forms of political, legal, economic and epistemological resistance by non-
governmental organization, governments and intellectuals in the so-called Global South.  
The communities, which have been affected by cases of biopiracy, thus range from India 
and Madagascar to Africa and South-America. Significantly, most of the patents on traditionally 
used medical plants of indigenous communities were granted by Western corporations in the 
1990s. Among the patent cases of the 1990s, the so-called Maya ICBG controversy was the first 
to draw attention to the difference between bioprospecting – the discovery and subsequent 
commercialization of products on the basis of biological resources – and biopiracy. The Maya 
ICBG controversy took place in 1999/2000 and revolved around the ethnobiologist Brent Berlin, 
who headed the International Cooperative Biodiversity Group (ICBG). This group had originally 
set out to document the biodiversity of Chiapas (Mexico), and explore the ethnobotanical 
knowledge held by the Maya in this region. Bioprospecting hence involved not only a mere 
survey of the biodiversity, but also hinged on surveying the knowledge of this biodiversity held 
by an indigenous community. This surveying, moreover, was clearly meant to result in the 
commercialization of this knowledge, the profits of which would not include the Maya as the 
original owners of this medical knowledge.   
Another case which has been highly significant for the current debate on biopiracy and 
the related notions of intellectual property rights (rights which were often denied to indigenous 
communities) is the controversy surrounding the neem tree, which can be found in both India and 
Nepal. A patent which centered on extracts of the neem tree as agents effective in fighting the 
fungal infections of plants was originally secured, in 1994, by the US department of agriculture in 
collaboration with WR Grace, a company based in Columbia, Maryland, featuring a pharma and 
biopharma product line. This patent, however, was subsequently opposed by Indian physicist 
Vandana Shiva as well as different groups within the US, Europe and India, among them the EU 
Green Party and the International Federation of Organic Agriculture Movements (IFOAM). In 
order to understand some of the epistemological underpinnings of the debate around biopiracy, it 
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is important to note that these groups were eventually able to prove that the knowledge of the 
fungicidal quality of the neem tree had long been held by Indian traditional medicine. Once such 
prior knowledge could be used, the patent – based on an American discovery of the fungicidal 
qualities of the neem tree – no longer held water. WR Grace lost an appeal in 2005.   
Another highly publicized case involved the attempted patenting of some hybrids of 
Basmati rice by the American corporation RiceTec in 2000. The damage resulting from the 
granting of this patent was immense in India: Indian farmers were deprived of the intellectual 
property and the knowledge they had held, over many generations, about the qualities and the 
farming of basmati rice. Indian companies which had hitherto exported basmati rice were 
threatened by bankruptcy; and American consumers thinking they had bought Indian rice were 
unaware of the fact that they had now in fact bought an American product. Through its 
intervention, the Indian government was able to invalidate some of the claims. The European 
commission subsequently set out to protect basmati rice, referring to regulations with regard to 
geographical indications. In order to prevent future cases, in which Indian traditional knowledge 
of plants could be patented by Western corporations, the Indian government drafted the 
Protection of Plant Varieties and Farmers’ Rights Act 53 in 2001, relating it to regulations 
aiming at the protection of biodiversity.  
In some cases involving the patenting of indigenous knowledge by Western corporations, 
indigenous communities have fought for being allowed to share at least a small percentage of the 
profit which is then made through the commercialization of this knowledge. In South Africa, the 
hoodia plant found in the Kalahari Desert was discovered to be an appetite suppressant, a quality 
which had long been known to the San people in South Africa. When in 1996, Unilever 
proceeded to manufacture a product based on hoodia, in collaboration with the South African 
Council for Scientific and Industrial Research, it was originally agreed that the San would not be 
included in the profit. However, in 2003, the South African San Council was successful in 
securing a share of 6-8% of the profit made through the sale of hoodia-related products.  
Yet, as of 2017, many attempts to counter forms of biopiracy have remained unsuccessful. 
For instance, the US-American company PureWorld Inc. holds a number of patents related to the 
use of Maca, whose medicinal power is documented to have been known by Peruvian indigenous 
communities since the sixteenth century. Consequently, the Peruvian government organization 
INDECOPI (National Institute for Defense against Competition and the Protection of Intellectual 
Property) has accused PureWorld of engaging in biopiracy. Yet, the patent has so far not been 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
12 
 
revoked. Examples like these provoked a multitude of activities which resulted not only in 
legislative measures of affected nations but also global efforts to ban biopiracy such as the 
Nagoya protocol. 
To be fair, it should be mentioned that biopiracy is not a general practice of 
pharmaceutical companies. On the other hand, the efforts of companies willing to commercialize 
herbal products based on indigenous knowledge according to the rules of fair benefit-sharing 
failed sometimes because of non-sufficient administrative infrastructures and individual attempts 
of corruption. The rare examples of biopiracy by multinational companies and corruptive 
elements in the Third World are, however, prominent and may have occasionally contributed to a 
poisoned atmosphere of mutual mistrust. Misleading developments like these illustrate once more 
the necessity to enforce the establishment of international regulations for the protection and fair 
use of indigenous knowledge on traditional medicines. 
 
3 Towards a One-World Medicine  
In this section, we will pinpoint aspects of contemporary life science research and relate to the 
question, how the knowledge of indigenous communities can be integrated in health care systems 
based on Western medicine. We argue that the term and concept of a One-World Medicine can be 
used as an ethically and socially acceptable alternative to forms of biopiracy. As a matter of fact, 
there are various medical concepts realized in the Western world, which differ from conventional 
medicine. These concepts deserve a closer look to decide, whether elements of them are valuable 
to be converted for the construction of a One-World Medicine. 
 
3.1 Concept of complementary and alternative medicine  
In industrialized countries, where conventional, science-driven medicine replaced traditional 
medicines several decades ago, there is a striking demand of the general public nowadays for the 
methods and practices of traditional medicine. Interestingly, all forms of non-conventional 
medicines often labeled as “complementary methods” of medicine or healing attract more the 
well-earning, settled people of middle class societies (Greten, 2005). The demand for green 
medicine with gentle natural remedies seems to be associated to an increasing reluctance towards 
synthetic chemical drugs and technomedicine.  
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While the interest in green medicines is tremendous, it is actually not quite clear, what it 
is. All kinds of non-conventional medicines can be summed up as complementary and alternative 
medicine (CAM). They can be categorized as (1) natural products (herbs, vitamins, minerals, 
probiotics) and (2) mind and body practices (acupuncture, music and massage, yoga, tai chi, qi 
gong, chiropractic and osteopathic techniques, meditation, movement techniques, relaxation 
techniques, and many other techniques), which augment conventional medical treatments. This 
vast collection of disparate and unrelated therapies are applied not only to prevent and treat 
diseases and ailments, but also to enhance quality of life (Ernst and Hung, 2011).  
As a matter of fact, the current lack of regulations leaves consumers at the mercy of those, 
who promote unproved remedies. The general perception that herbal products were safe may lead 
to inappropriate use with unforeseeable consequences for consumers (Consolini and Ragone, 
2010; Yusuff and Tayo, 2011). The term CAM implies two different approaches: Complementary 
medicine as the use of non-conventional treatments may be used together with conventional 
medicine, while alternative medicine is used instead of conventional medicine.  
The popularity of CAM was recognized by some governments of industrialized countries, 
and research institutes investigating the scientific basis of CAM therapies have been founded. 
Selected examples are the National Center for Complementary and Alternative Medicine 
(NCCAM) in USA - later on re-established as National Center for Complementary and 
Integrative Health (NCCIH) and the National Institute of Complementary Medicine (NICM) at 
the University of Western Sydney, Australia.  
 
3.2 Concept of self-medication  
Herbal medicines are frequently sold as over-the-counter (OTC) products (Agbabiaka et al., 
2016). Such herbal products are classified as dietary supplements, but not as drugs. Therefore, 
manufacturers do not have to provide proof of efficacy or safety before selling these products. 
Their efficacy and safety is therefore doubtful. There are potential risks of self-medication, e.g. 
incorrect self-diagnosis, delays in seeking medical advice when needed, severe side effects, 
harmful herb-drug interactions, the risk of addiction and abuse etc. (Ruiz, 2010). There is still 
limited evidence on safety and efficacy of the estimated over 20,000 herbal products available in 
the market. It is imperative that more stringent regulations and guidelines are required to 
guarantee safety and efficacy of such products (Bent and Ko, 2004). Scientific evidence is needed 
to determine pharmacological activity, stability, and bioavailability of these products.  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
14 
 
Laws pertaining to the labeling of dietary supplements prohibit specific claims for 
treatment or prevention of diseases. These products are nevertheless widely applied as CAM 
therapies (Glisson and Walker, 2010). In fact, dietary supplements are frequently taken by 
patients at their own discretion without knowledge of their physicians. Patients may 
underestimate the risks of self-medication and may anticipate physicians' disapproval to use OTC 
products. For physicians, it is imperative to ask patients about their use of CAM products. 
However, even if physicians are aware of it, they frequently feel poorly trained to judge on safety 
and efficiency of herbal preparations (Vora and Mansoor, 2005). The problem becomes even 
aggravated, if cross-reactions of herbal preparations with each other, with the diet of a patient, or 
with conventional medications are at stake. Physicians from conventional medicine therefore tend 
to generally prohibit patients the intake of CAM products – a situation which does merely 
increase confidence of patients and further favors the concealment of intake of CAM products by 
patients. This may cause vicious cycles, which have to be disrupted. 
 
3.3 Concept of integrative medicine 
Paradoxically, about 90% of the current conventional drugs are not active in approximately 40% 
of patients (No authors, 2012). Furthermore, it has long been recognized and still is a major 
problem to control and avoid adverse drug reactions of conventional drugs, leading to a situation, 
in which thousands of patients still die due to the improper use of therapeutic substances 
(Lazarou et al., 1998; Rolfes et al., 2017). Surprisingly, the principles of evidence-based 
medicine have seemingly not been applied for all conventional drugs. The lack of efficacy of 
numerous conventional drugs in all patients led to the current concept of personalized or 
precision medicine. The vision is to develop individualized treatment options for each single 
patient to reach higher treatment efficacy and with less side effects (Paul and Roses, 2003). 
Personalized medicine is, however, not a new concept of conventional medicine, but practiced in 
all traditional medicines for ages. This is another clue that both systems, traditional and 
conventional medicines should reflect on their specific advantages and disadvantages and that 
merging of systems may be beneficial for the patients.  
 The main idea of integrative medicine is to combine CAM with evidence-based 
conventional medicine (Snyderman and Well, 2002; May, 2011). While conventional medicine as 
discipline of modern life science in general follows reductionistic principles, integrative medicine 
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considers the patients in his/her entirety. According to this perception, diseases are caused by 
much more than reductionistic erroneous biochemical reactions or DNA mutations. Here, a 
holistic principle stands in the foreground. The body-mind-soul balance of the patient plays an 
important role. Therefore, integrative medicine focuses not only on direct disease treatment, but 
also on the wellness and lifestyle of patients. Ideally, integrative medicine is more than the 
addition of conventional and non-conventional approaches. Their right combination generates 
synergistic healing powers in the patient. Health is more than the absence of disease. In this 
context, the patient-physician relationship gains specific relevance.  
Though the concept of integrative medicine is practiced at many places worldwide, an 
impressive example of a leading consortium for integrative medicine represents the Consortium 
of Academic Health Centers for Integrative Medicine with more than 60 US hospitals, including 
the John Hopkins School of Medicine, the Duke University of Medicine, the Georgetown 
University School of Medicine, the Mayo Clinic and many others.  
Since 2012, the Swiss basic health insurance partly reimburse expenses from listed drugs 
belonging to CAM (i.e. phytotherapy, traditional Chinese medicine, neural therapy, 
anthroposophy, homeopathy), if done by a certified physician. Recipes not acknowledged by the 
basic insurance and therapies from non-medical practitioners may be reimbursed by 
supplementary and optional health insurances (Klein et al., 2015). The CAM medication is 
cheaper, but the consultation times are longer compared to conventional medicine. Hence, the 
overall costs are similar for both in Switzerland (Busato et al., 2006). CAM is accepted by over 
90% of patients as treatment option and about half of the population prefers hospitals offering 
services both from conventional medicine and CAM. The vast majority of the population (85%) 
agrees that expenses for CAM are reimbursed by the basic health insurance (Wolf et al., 2006). 
About half of the patients have used CAM because of fewer side effects and lack of satisfaction 
with conventional medicine (Quattropani et al., 2003). Interestingly, women in the age range of 
25-64 years and people with higher educational levels prefer CAM services (Esch et al., 2008; 
Klein et al., 2007).  
Although the German government included naturopathy and homeopathy into the 
Germany Medical Licence Act in 1988, they have not been integrated in the academic teaching 
and practice as of yet (Albrecht, 2013). This is astonishing, since herbal medicine and 
naturopathy is even more popular in Germany than in Switzerland and also Austria (Brinkhaus et 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
16 
 
al., 2011). Similar to Switzerland, German CAM users are more frequently women, have higher 
education levels, are more physically active and rarely over-weight (Schwarz et al., 2008). A 
negative aspect is certainly that more than half of the patients do not inform their general 
practitioners about their use of CAM (Schnabel et al., 2014). Hence, unintended herbal-drug 
interactions may occur without sufficient recognition by the physician.  
 
3.4 Concept of traditional medicine 
Since prehistoric times, all human societies and communities gathered knowledge on how to deal 
with diseases and ailments. Herbal practices may be categorized into (Elumalai and Eswariah, 
2012): 
1) Shamanic practices: The practitioner disposes of magical capabilities and uses plants as 
tools to interact with supernatural powers spirits and to cure patients. In this context, it is 
only of secondary relevance, whether or not the used plants reveal indeed 
pharmacological activity in a scientific sense. 
2) Energetic practices: Herbs contain energetic power that restore the misbalanced energy in 
diseased subjects. This concept of herbal usage is practiced in TCM, Ayurveda and Unani 
etc. 
3) Functional dynamic practices: Herbs reveal functional activities that provoke 
physiological consequences, although the underlying principles are not necessarily 
physically or chemical defined agents. 
4) Rational phytotherapeutic practices: Herbs exert medical activity because of their defined 
chemical constituents and pharmacological modes of action. Phytochemical cooperative 
by synergistic interactions in plants or herbal mixtures. 
Traditional medicine represents one of the most important cultural achievements of mankind 
during history before the rise of modern medicine. The World Health Organization (WHO) 
defines: “Traditional medicine is the sum total of the knowledge, skills, and practices based on 
the theories, beliefs, and experiences indigenous to different cultures, whether explicable or not, 
used in the maintenance of health as well as in the prevention, diagnosis, improvement or 
treatment of physical and mental illness” (WHO, 2000). To this end, traditional medicines 
comprises of all forms of formalized and documented practices and remedies in a community or 
society as well as all forms of informal practices, orally handed down from generation to 
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generation. There is a wide range of traditional practices, including herbal mixtures, processed 
herbal materials (essential oils, fresh juices, gums and resins etc.) and herbal extracts (fluid or dry 
extracts, tinctures, decoctions and infusions, oils etc.). Traditional Chinese medicine is largely 
based on the balance of powers in the body, e.g. the five elements, yin and yang etc. (Efferth et 
al., 2013). In addition to herbal medicine, Asian forms of traditional medicine can also comprise 
of reflex therapies such as acupuncture, manual therapies, dietetics, spiritual therapies and others.  
In Africa, animism is far distributed, i.e. the belief that all living and non-living subjects 
in nature bear supernatural spirits, which maintain health. Therefore, traditional healing attempts 
to restore the spiritual balance of patients. Plants are not believed to exert curative effective 
because of their pharmacological activity, but because of the healer’s capability to influence the 
spiritual relationship between the patient and his environment (Anyinam, 1987). Herbalists in 
Arab countries prefer medicinal plants that are well documented in the Arab-Muslim tradition 
(Khalid et al., 2012). Some national herbal pharmacopoeia (such as the Moroccoan) contain 
numerous of these plants (Bellakhdr, 1997). Herbal medicines also represent valuable assets to 
conventional medicine in Middle and South America (Berman et al, 1999; Hunt et al., 2000). 
Remarkably, even in Western medicine many long established drugs were initially 
derived from medicinal herbs, e.g. opium, aspirin, digitalis, quinine and many others. WHO 
provided data that about one quarter of all modern drugs are plant-based (WHO, 2007). Even 
more striking, the usage of 80% of plant-based bioactive compounds in conventional medicine 
today correlate to their traditional ethnopharmacological use of the corresponding medicinal 
plants (WHO, 2013). This relationship emphasizes the potential relevance of medicinal herbs for 
modern medicine (Newman and Cragg, 2012; Cragg et al., 2014). 
Therefore, it does not come as a surprise that the importance of natural resources for 
modern drug development process has also been appreciated by the Nobel Assembly of the 
Karolinska University in Stockholm, Sweden. The Nobel Prize in Physiology and Medicine 2015 
was given to three scientists for their breakthrough inventions in the field of natural product-
based drug development, especially in the field of communicable tropical diseases (Efferth et al., 
2015). The so-called neglected tropical diseases especially worth mentioning are widely 
distributed in tropical and subtropical areas, where prevention and cure for these diseases are not 
sufficiently available. Here, phytotherapy and natural products bear high therapeutic potentials 
for their treatment. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
18 
 
Evidence-based medicine is thought to be a gold standard in conventional medicine, 
though it can be critically noted that this is not true for all western drugs. Nevertheless, it is 
common sense that the principles of evidence-based medicine should also be applied for 
traditional medicines. According to WHO, the “inappropriate use of traditional medicines or 
practices can have negative or dangerous effects” and “further research is needed to ascertain the 
efficacy and safety” of traditional practices and herbal preparation.35 As a matter of course, 
phytotherapeutic remedies should meet stringent criteria of quality control, elucidation of modes 
of action, as well as clinical safety and efficacy. 
There are three major requirements for herbal medicines to be defined as conditions to 
integrate traditional medicines into conventional medicine. They can be understood as pre-
conditions to generate convincing approaches for One-World Medicine, i.e. (1) the traditional 
knowledge of healers and shamans is increasingly getting lost. This knowledge has to be 
preserved, (2) standardization and quality control of herbal products and (3) clinical proof of 
safety and efficacy in patients.  
 
3.5 Concept for developing countries and beyond: One-World Medicine  
WHO repeatedly reported during the past years that up to 80% of human beings in developing 
countries rely on traditional herbal medicines for primary health care (WHO, 2007; 2013). 
Patients with less income, less education and patients from rural areas are more likely to use 
traditional medicine (Oyebode et al., 2016). Not only that Western medicine is frequently not 
affordable and that traditional medicine is available at low prices for primary health care in 
developing countries. In many rural areas, hospitals are only reachable over far distances and the 
patients are frequently confronted with long waiting queues with common waiting times of 6-12 
hours. Therefore, many patients rather rely on the reputation of healers and their traditional 
practices. Traditional medicine represents a remarkable reservoir for the drug development 
process (Zaenker and Entschladen, 2009). 
This puts the responsibility on scientists and physicians alike to explore the scientific 
basis for a safe and efficient use of traditional practices. On the other hand, it is estimated that the 
vast majority of the estimated 30,000-70,000 medicinal plants worldwide have not yet been 
scientifically investigated (Verpoorte et al., 2005). The research-driven modernization of 
traditional medicines represents a primary goal to make them globally available, affordable and 
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safe. Based on the concept of integrative medicine, a comparable concept can be envisioned for 
the global use of traditional medicine embedded in and amalgamated with conventional medicine. 
The synopsis of medical knowledge from all around the world allows generating novel treatment 
options, which may be more suitable to the needs of the majority of the population on earth 
without access to expensive therapies which are exclusively reachable for rich minorities in the 
industrialized countries. Such a One-World Medicine might be able to link together the best of 
both worlds – conventional medicine from the developed in the North and scientifically proven 
efficient, safe and more affordable traditional medicines from the under-developed South 
(Efferth, 2010). The ultimate goal is to provide safe and efficient medical care to under-served 
populations in developing countries. 
The health care systems of Third World countries frequently cannot afford the high costs 
for medical treatment for their populations. Sufficient health care is too often a privilege for rich 
elites not only in industrialized, but also in developing countries. Hence, the population is 
frequently left alone with their heritage of traditional medicine brought down from their 
ancestors. As a consequence, the majority of the world population without sufficient access to 
modern drugs relies on natural medicines. While there is no doubt about the considerable 
potential of traditional medicines, they have been largely used without stringent medical and 
scientific control to ensure safety and efficacy and without the rigorous rules necessary to register 
drugs nowadays in a comparable manner to conventional western drugs. This desperate situation 
illustrates the urgent need for evidence-based approaches for traditional medicines. Therefore, the 
establishment of rationale phytotherapies seems to be a major plausible option for the future 
(Efferth, 2012; Efferth and Koch, 2011; Efferth and Greten, 2012a; 2012b; Efferth et al., 2007).  
Facilitating global interconnectedness certainly poses tremendous challenges, but it also 
represents an encouraging vision to empower impoverished indigenous communities to achieve 
long-term improvements in primary health care. The goal is to provide high quality and at the 
same time affordable healthcare to people in the regions, where they live. The care the people are 
receiving should be audited by partners and reviewed by medical advisory boards. The 
establishment of medical centers specifically designed to provide quality healthcare to poor 
people may serve as a model in this respect (OneWorldHealth, 2016). 
If herbal medicines meet rigorous quality control in production and evidence-based 
standards, they would not only provide safe and efficient drugs to the Third World, but also 
reduce costs for the health systems in industrialized countries. Faced with ever-increasing costs 
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for medications, One-World Medicine also bears considerable potentials for future health care in 
the Western world in times of bursting in health systems (Efferth, 2010). 
In most countries of Africa, Middle East and South America, herbal medicine is not yet officially 
acknowledged by the governmental health care systems. Health insurances do not cover the costs 
even for registered herbal drugs. They are accounted as food supplements and are widely used 
outside the official health systems. WHO has defined guidelines for the institutionalized 
integration of traditional medicine into the official health system. These guidelines include: 
1. Political recognition by government 
2. Development of legal and regular frameworks 
3. Scientific research on traditional medicine 
4. Protection of intellectual property on traditional medicine 
5. Dissemination of information and education on traditional medicine of the general public 
6. Creating economic opportunities for traditional medicine (WHO, 1978). 
The Division of Traditional Medicine, a collaborating center of WHO and recognized by the 
Organization of African Unity, has started activities for the identification of natural areas to grow 
medicinal plants (Keita, 1993). The WHO Regional Committee for Africa released a resolution 
(AFR/RC50/R3) to support the integration of traditional medicines, if safety, efficacy and quality 
is evident (WHO, 2001). Other resolutions followed, e.g. the Abuja Declaration and the 
declaration of the organization of African Unity in 2001 (Abuja Declaration, 2001) and others.  
 While traditional medicine was sometimes banned in the past by the governments (i.e. the 
Apartheid regime in South Africa had forbidden herbal practices by the Witchcraft Suppression 
Act of 1957 and the Witchcraft Suppression Amendment Act of 1970), traditional medicine 
reached a more official status with more formal regulations in the past few years.  
 However, in some African countries such as Botswana and Mozambique, the traditional 
healthcare systems enjoy official status and in these countries a more formal trade exists. 
Botswana, Namibia, Mozambique, Zimbabwe and Malawi import medicinal plants form South 
Africa (Economic Commission for Africa, 2008).  
In South Africa, the expenses for services of traditional health practitioners are not 
covered by the official Basic Conditions of Employment Act (BCEA) (Mbatha, 2012). The trade 
of crude medicinal plants is not regulated. However, once a health-related claim is made for a 
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finished product, it has to go through the full drug evaluation procedure in the Medicines Control 
Council (MCC) before marketing (Sharad et al., 2011). 
Under the present health care reform of the Federal Government of Nigeria, traditional medicine 
is recognized as important segment of the primary health care system. The Federal Government 
of Nigeria has established the Nigeria Natural Medicine Development Agency (NNMDA) to 
promote Nigerian traditional medicine products and practices and to integrate traditional 
medicine into the mainstream of modern health care system. The Nigerian Ministry of Health 
encouraged the University of Ibadan to perform research on medicinal herbs to foster 
standardization and regulation of traditional medicine (Ekeopara and Ugoha, 2017). 
Ethiopia supports the sustainable use of plant resources. This is part of broader political strategies 
including environmental protection, development of natural resources and diversification of 
domestic and export commodities (Srivastava et al., 1996). 
In Ghana, the National Health Insurance Scheme (NHIS) from 2003 does not cover traditional 
medicine services (Barimah, 2013). Although prescription and dispense even of certified herbal 
products is not supported, the integration of standard Western medicine and herbal medicine is 
recommended (Bodeker, 2001).  
In the meantime, more than 30 African countries implemented national policies on 
traditional medicine into the official health systems and more than 20 countries developed legal 
frameworks for traditional medicine practices (Kasilo et al., 2010). It remains to be seen, to what 
extent these national policies and regulatory frameworks will be translated to medical routine in 
everyday life.  
Governmental support for the integration of herbal medicines into the official health care 
systems represents only a part of the aspects that have to be considered (Ochwang’i and Oduma, 
2017). Physicians trained and educated in Western medicine also have to accept practices from 
herbal medicines (Bodeker, 2001; Awodele et al., 2012; Puoane et al., 2012). These integration 
processes may be slow and troublesome but worth attempting (Bodeker, 2001; Lee, 2016). On the 
other hand, many traditional medicine practitioners would like to have some kind of formal 
education both in Western medicine and herbal medicine, which provides excellent chances for 
concepts of integrative one-world medicine (Bruce, 2002).  
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Japan may represent a showcase example for the concept of one-world medicine. Japanese 
traditional medicine known as Kampo medicine is integrated into the official health care system. 
Conventional medicine and Kampo are subject to the same strict regulations (Maegawa et al., 
2014; Hakamatsuka, 2017). The National Health Insurance Reimbursement System contains 148 
Kampo recipes that are prescribed by physicians. The medicinal plants and extracts are described 
in the Japanese Pharmacopeia, and strict quality standards are set by law. Physicians easily use 
both Western and Kampo medicines in their daily practice. According to recent investigations, 
more than 80% of the Japanese physicians prescribe Kampo formulae and 73-84% of patients 
take Kampo drugs (Moschik et al., 2012; Hottenbacher et al., 2013). Kampo is preferentially used 
for chronic ailments than acute diseases, e.g. common cold, gastrointestinal complaints, stress 
and anxiety etc. (Hottenbacher et al., 2013).  
In China and Taiwan, the costs for services of traditional Chinese medicine are partly 
covered by health insurances. The costs for academic medicine are higher than for practices of 
Chinese medicine (herbal remedies, acupuncture etc.) (Liao et al., 2012). More than 60% of 
patients use Chinese medicine (Chen et al., 2007). While self-treatment of chronic diseases seems 
to be most attractive for patients, most cancer patients also use Chinese medicine in addition to 
Western medicine (Liao et al., 2013; Wu et al., 2015).
 
Socio-demographic studies showed that 
herbal medicines, which are cheaper than conventional drugs, are popular among under-insured 
patients (Chung et al., 2013). The further integration of Chinese medicine into the national health 
care systems became a national policy in China to save expenses. The national “essential drug 
list” contains more than 200 formulated herbal drug and 1100 herbal preparations. The financial 
budget for Chinese medicine doubled from 2011 to 2014 to 4.66 billion USD, which may be 
taken as a strong indicator for the willingness to integrate Chinese medicine into the official 
health care system (Dang et al., 2016).  
Brazil, with its 8.5 million km
2
 of land area and a coastline around 8,500 km long, is a highly 
privileged country as to the variety and number of species that are home to six major terrestrial 
biomes: Amazon, Caatinga (an genuine Brazilian extremely environment), Cerrado (a type of 
savanna), Atlantic Forest, Pantanal and Pampa, besides the three marine ecosystems, twelve 
major hydrographic regions (MAA, 2011), and the mangroves that constitute a intermediate 
biome between terrestrial and marine environments. This biological wealth can be translated into 
a great diversity of molecular models produced by thousands of organisms that compose the 
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Brazilian biodiversity. This "natural molecular factory" still been completely unexplored, 
consequently, is a potential source of new bioproducts, such as pharmaceuticals, cosmetics, 
agrochemicals. With great chemo-biological wealth, Brazil was one of the 192 countries 
signatories of the Convention on Biological Diversity (CBD), during the Rio de Janeiro United 
Nations Conference, which held on 5 June 1992, in Rio de Janeiro, Brazil. This meeting was 
stated for the signature at the Earth Summit, and inputted into force on 29 December 1993. 
Representatives of all nations had committed themselves to the conservation of biological 
diversity, its sustainable use, and the just distribution of the benefits of economic uses. Approved 
by the National Congress, the CBD was the starting point for the creation of Law Decree No. 
2519 of March 1998. With the publication of this Decree, Brazil formally assumed that the 
Biodiversity Law would be put into practice and implemented. However, the lack of a legal 
framework made it quite difficult to be implemented. Thus, this legal problem became an 
obstacle for the country to sign the Nagoya Protocol, which came into operation in October 2014. 
This new pact, an outgrowth of the Convention on Biological Diversity, ratified by 50 countries, 
was intended to implement the measures defined by the Convention. In order to protect 
biodiversity and curb biopiracy, Brazil has stepped forward, being one of the first countries to 
establish a Regulatory Law for Access to Genetic Resources based on the CBD.  
The President of Brazil, with the justification of prohibiting bio-piracy, issued the 
Provisional Measure - MP 2186-16 (MP 2052/2000) and it has become public in August 2001. 
This MP has gained force of law, at the moment in which it was edited the Constitutional 
Amendment 32 of 11 of September of 2001. The MP 2186-16 was decreed by law in May 2015, 
when Law No. 13,123 of 20 May 2015, also known as the Biodiversity Law, was approved by the 
President of Brazil, Dilma Rousseff. The stated intention of the Biodiversity Act was to avoid 
bio-piracy and ensure the sharing of benefits in a "fair" and "equitable" with indigenous peoples 
on the innovations arising from our biodiversity. The regulation was published, after intense 
negotiations with the scientists, private sector, ministries and communities involved, but still 
remain doubts as will be implemented. 
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3.6 Conditions to realize One-World Medicine 
3.6.1 Preservation of traditional medicinal knowledge 
Although certain traditional medicines are increasingly booming worldwide (e.g. traditional 
Chinese medicine, Ayurveda), traditional knowledge on other natural medicines is endangered, 
because the knowledge of shamans and traditional healers is getting lost, since their oral 
traditions handed down for thousands of years is getting more and more extinguished nowadays. 
With progressing economic development in tropical and subtropical countries, the offspring of 
traditional healers and shamans may be less motivated to take over the same profession as their 
parents. Although shamans are highly respected persons in their communities, many young 
people seek their fortune in urban cities rather than spending a life as shamans in rural 
environments. Sometimes there is considerable reluctance of herbalists to talk about their 
traditional medical knowledge, because they argue that their knowledge could be stolen by 
pharmaceutical companies. Though such threats may be justified, this attitude might foster the 
loss of knowledge for further generations. Hence, the death of each traditional healer represents 
an irretrievable loss of age-old medical knowledge. 
An approach to prevent the loss of traditional knowledge is the systematic performance of 
ethnobotanical and ethnopharmacological field studies to collect all kind of information on herbal 
medicines, their preparation and traditional uses for diseases, adverse side effects etc.). These 
data can be compiled and made available by the establishment of electronic databases as recently 
demonstrated (Johnson, 2002; Babu et al., 2006; Latheef et al., 2008). 
Traditional medicines are also threatened by the destruction of rainforests and other 
biological biotopes, which irreversibly leads to a loss of plant resources and also destroys the 
living spaces of indigenous tribes with their knowledge on herbal medicine and traditional 
practices. Further reasons that may negatively impact the use of traditional medicinal herbs 
include environmental pollution, the anthropogenic invasion of foreign species into biotopes, and 
more recently consequences of climate change, which all may contribute to the displacement of 
indigenous species (Newman, 1994; Forest et al., 2007; Cavaliere, 2009). 
 
3.6.2 Sustainable production medicinal plants and phytochemicals 
A considerable problem, if medicinal herbs are used not only in small local communities but at 
larger scales, is overharvesting of plants growing in the wild. This may not only lead to 
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extinguishing plant species and progressing destruction of biodiversity, but also to bottlenecks in 
sustainable supplies of plant material for national and international markets (Li et al., 2007). 
A promising concept to reduce another societal problem in Africa, i.e. ivory-poaching of 
elephants and rhinoceroses, is to establish protected reserves and to provide jobs to the 
indigenous population by their employment as rangers and sometimes even establishing novel 
gendered identities at the same time like in a bespoke all female anti-poaching unit, Black 
Mambas (http://www.blackmambas.org/, accessed on June 20
th
, 2017). It can be envisioned that 
comparable concepts might also be applicable to herbal medicine. The controlled cultivation of 
medicinal plants in plantations and greenhouses provides numerous advantages: (1) jobs for 
indigenous people, (2) protection of medicinal plants from being extinguished by over-harvesting 
in the wild, (3) better quality of herbal material due to standardized cultivation and harvesting 
conditions, (4) sustainable production to maintain supply sufficient amounts of herbs for primary 
health care in developing countries etc. 
Specific guidelines for good field collection practices for medicinal plants have been 
developed (Fong, 2002). Education and training of local people may facilitate and support plant 
conservation (Busia, 2005; Frenkel et al., 2005). If indigenous people understand that 
uncontrolled harvest of medicinal herbs from the wild foster the ultimate extinction of plant 
species and, therefore, shorten their economical basis, strategies for sustainable cultivation of 
herbs may be easier realized. 
 Avoiding wild collections by culturing medicinal plants in fields and greenhouses may 
have more advantages (Delabays et al., 2001). Cultivation conditions (temperature, humidity, soil 
etc.) are well-known to influence the yield of the desired chemical constituents in plants. Hence, 
the optimization of the specific cultivation conditions in greenhouses may result in higher yields 
of natural product contents in medicinal plants. 
Modern techniques adapted from classical agriculture and horticulture can also be applied 
for the cultivation of medicinal plants such as the breeding of high-yield cultivars at optimized 
culture conditions. Naturally occurring individual variations of plants can be exploited due the 
specific selection of strains with higher amounts of the phytochemicals of interest. One may take 
advantage of classical breeding techniques to cross high yield clones and to generate synthetic 
variants of medicinal plant species. Another option may be the cultivation of genetically 
modified, transgenic plants, which reveal substantially higher amounts of natural products 
compared to their wild-type counterparts (Muntendam et al., 2009). From an economical, 
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ecological and ethical point of view, however, the conservation of the genome information of 
traditional breeds and wild-types will be another task, which needs to be accomplished, if we 
want to preserve genetic diversity. 
Seed, germplasm and DNA banks are important means for the conservation of endangered 
plant species. An example is China’s first national seed bank for wild plants at the Kunming 
Institute of Botany, which contains some 30,000 seeds 
(http://www.bgci.org/resources/news/0716/). 
The slow growth of medicinal plants may limit their commercialization. Solutions to this 
problem may represent the total chemical synthesis, the semi-synthesis from isolated precursors, 
or the systematic derivatization of natural lead compounds to obtain generate pharmacologically 
improved drugs (Kowole et al., 2008; Szpilman and Carreira, 2010). This, however, cannot be 
regarded as traditional medicine anymore, but as classical pharmacological drug development 
inspired by drugs from nature. Furthermore, total synthesis can be time-and cost-consuming and, 
therefore, not applicable for industrial large-scale production (Schmid and Hofheinz, 1983). 
It is not out of reach for some developing countries also to consider biotechnological 
techniques to enhance and accumulate natural products (Efferth, 2011; Gandhi et al., 2015). 
Hairy root cultures of medicinal plants are easy to maintain and produce large amounts of natural 
products (Mehrotra et al., 2015). The same is true for suspension or callus cultures derived from 
medicinal plants (Georgiev et al., 2009; Ogita, 2015). With the help of molecular biology, entire 
biosynthetic pathways for natural products can be expressed in biotechnologically applicable 
microorganisms, i.e. Escherichia coli or Saccharomyces cerevisiae etc. (Julsing et al., 2006). A 
famous example for the success of this technology is the production of the antimalarial drug 
artemisinin from the Chinese medicinal plant, Artemisia annua L. (Zeng et al., 2008). 
 
3.6.3 Standardization and quality control of herbal products 
Herbal recipes frequently consist of complex mixtures of different plant. The composition and 
amount of chemical constituents may vary even within one and the same species, depending on 
climate, soil composition, habitat altitude etc. Herbal products should therefore reach a similar 
degree of reproducibility as any other approved synthetic drug as well. To reach this goal, 
internationally accepted standards need to be established (Efferth, 2010). Three main levels of 
standards can be defined: (a) Quality control of herbal product materials, (b) preclinical evidence 
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of safety and efficacy, and (c) clinical evidence of safety and efficacy. It is however, not only 
about the standardized constitution of herbal mixtures, there is also a lot of concern about 
intentional adulterations or non-intentional contamination, which have to be taken as alarming 
signs to set high quality standards (Efferth and Kaina, 2011; Efferth and Greten, 2012c).  
International standard setting has to consider several levels:  
(1) The correct identification of medicinal plants is of utmost importance (de Jong et al., 2015), 
since wrongly identified plants may not only be without therapeutic effect, but even worse may 
contain poisonous ingredients. Botanical misidentification or mislabeling of herbal material 
might exert toxic reactions in human subjects (Booker et al., 2016; Osathanunkul et al., 2016). 
(2) Standardization of production of herbal prescriptions by international quality guidelines such 
as Good Sourcing Practice (GSP) to guarantee authentication of medicinal plants, Good 
Agricultural Practice (GAP), Good Laboratory Practice (GLP), Good Manufacturing Practice 
(GMP), and Good Clinical Trial Practice (GCTP) (Zhang et al., 2010; Franz et al., 2011). 
(3) Chemical analyses to detect and avoid contamination of herbs with mycotoxins, pesticides, 
heavy metals, other chemical toxins, and radioactivity taken up from the soil as well as organic 
solvents and microbial contamination due to unprofessional processing of harvested herbs 
(Posadzki et al., 2013). 
(4) Chemical analyses to detect and avoid substitution or adulteration with other herbs or 
chemical drugs, which may deliberately occur for economic reasons. It is an illegal act to replace 
authentic herbs by faked ones, because it is cheaper, or to intentionally increase the activity of an 
herbal mixture by adding a synthetic chemical drug with well-known pharmacological activity 
(Efferth and Kaina, 2011; Posadzki et al., 2013). 
International regulations for herbal products will improve the safe and efficient use of 
traditional medicines. The WHO introduced quality control regulations to set standards and 
specifications for herbal materials (WHO, 1998). European Union (EU) regulated the production 
and distribution herbal medicines according to the European Directive on Traditional Herbal 
Medicinal Products (Efferth and Greten, 2012d). In the United States, herbal remedies are still 
frequently traded as dietary supplements. Herbal products of this category do not underlie the 
strict regulations for safety or efficacy. They are widely available without prescription as OTC 
products on the own expense of the patients (Eichhorn et al., 2011), although the corresponding 
governmental authorities may withdraw them from the market, if there is evidence for toxicity.  
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In many countries in Africa and Middle East, there are non-sufficient regulations for 
trading herbal products. As an example, medicinal plant products were sold in Akthar shops, 
where no special training was required for the persons responsible. Since 1986, it has been made 
mandatory that each Akthar shop must be registered by the local branch of the Ministry of Health 
to obtain the official permission to sell herbs. Promotion of these products with health claims is 
not permitted. In 2010, a regulation to license for traditional herbal medicinal products (THMPs) 
was published by the Turkish Medicines and Medical Devises Agency (TMMDA) and these 
products are subjected to a marketing authorization procedure within the scope of which the 
product quality, safety and efficacy for the defined therapeutic or preventive indications are 
evaluated. A scientific commission for examining application of THMPs was established under 
TMMDA. On the other hand, the Turkish market currently offers an ever increasing number of 
dietary supplements, which are assessed and authorized by the Ministry of Food, Agriculture and 
Livestock. Registration is done based on the manufacturer’s declaration. Manufacturers are 
prohibited to claim any medical indications. These products are not subject to any analysis and 
examination before going to market. Therefore, the quality, safety and efficacy have not been 
proven.  
Several institutions have been established in African countries to standardize herbal drugs, 
perform clinical trials and care about regulatory affairs, e.g. 
 Center for Scientific Research into Plant Medicine (Ghana). In Ghana, herbal medicine 
producers need a license by the national Food and Drug Administration. Only qualified 
ventors should be allowed to trade and sell herbal products (Aziato and Antwi, 2016).  
 Center for Research on Pharmacopoeia and Traditional Medicine (Rwanda); 
 “Village Chemist” for Development of Pharmacognosy, Obafemi Awolowo University, 
Ile-Ife (Nigeria); 
 Swaziland Center for Research in Medicinal and Indigenous Food Plants, university of 
Swaziland, Swaziland; 
 Department of Traditional Medicine, Bamako (Mali); 
 Center for Traditional Medicine and Drug Research (CTMDR) in Kenya Medical 
Research Institute (KEMRI). 
In India, the government established a National Medicinal Plants Board and the Ministry of 
Health and Family Welfare founded a department to deal with herbal medicine (Ministry of 
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AYUSH) (Elumalai and Ewariah, 2012). More than half a million traditional practitioners are 
licensed and registered by the Indian Medicine Practitioners Act. 
 
3.6.4 Mode of action analyses and network pharmacology 
It is not a trivial task to unravel the molecular modes of action of complex herbal mixtures, 
especially if one applies the one-drug-one mechanism concept which frequently used in classical 
pharmacology of synthetic drugs. The concept of mono-specific small molecules was and has 
been very fashionable since a couple of years, to increase the specificity of therapeutic drugs 
action and to decrease the non-specific toxic reactions to healthy normal tissues. Inspired by the 
theoretical idea to generate more specific and safer drugs, conventional pharmacologists 
sometimes called drugs from traditional medicine “dirty drugs”. There are numerous examples of 
approved drugs, e.g. for cancer therapy following this concept. This concept showed, however, 
only modest clinical success, because mono-specific drugs are easily prone to resistance 
development. Frequently point mutations in the monospecific drug target are sufficient to make a 
drug inefficient (Volm and Efferth, 2015; Patel et al., 2017; Lim et al., 2018). Here, the multi-
specific nature of medicinal plants and herbal mixtures provides a striking advantage. Because of 
a multitude of phytochemicals in plant extracts, numerous cellular targets are addressed, which 
makes the therapeutic effect much more efficient and robust against resistance development. 
Single mutations in singe target proteins will not hamper treatment success, because many 
different targets in the diseased cell are addressed. Therefore, multi-specific extracts of medicinal 
plants or herbal mixtures are more effective. It can be assumed that during evolution of life on 
earth, multi-specific approaches were more successful towards selection pressure than mono-
specific approaches. From an evolutionary point of view, the “dirty drugs” are the better drugs, 
because they better cope with resistance phenomena.  
The analysis of multi-specific modes of actions is much more complicated because of the 
complexity of numerous phytochemicals each addressing multiple target proteins. The advent of 
the so called omics technologies (genomics, epigenomics, transcriptomics, proteomics, 
metabolomics, lipidomics, glycomics etc.) allow the measurement of highly complex alterations 
upon treatment with herbal mixtures (Kadioglu et al., 2016; Li et al., 2018; Lin et al., 2018). 
Bioinformatical techniques are necessary to unravel affected signaling pathways and mechanisms 
in a plethora of single data points that are generated by these “-omics” approaches”. A new 
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discipline emerged termed “network pharmacology”, which focusses on the elucidation of 
complex modes of action (Schmidt and Efferth, 2016; Poornima et al., 2016; Efferth et al., 2017; 
Ulrich-Merzenich et al., 2017; Wagner and Efferth, 2017; Guo et al., 2018). It can be expected 
that many relevant advancements will be made in the understanding of the therapeutic effects of 
medicinal herbs and herbal mixtures.    
 
3.6.5 Herb-drug interactions 
An issue that should be adequately addressed is the interaction of some commonly used herbs 
with synthetic drugs from conventional medicine (Kober et al., 2008; Meng and Liu, 2014; Zuo 
et al., 2015; Liu et al., 2015; Choi et al., 2016). Due to the influence of herbal preparations with 
the metabolizing enzyme machinery in the liver, drug-herb interactions may lead to unexpected 
(increased or decreased) concentrations of therapeutic drugs (Woo et al., 2015; Dai et al., 2017; 
Lu et al., 2017). Between 50% and 63% of these interactions occurred between prescribed drugs 
and OTC herbal products (Glisson and Walker, 2010). The majority of cases showed mild 
pharmacokinetic interactions. However, the consequences of these interactions are not well 
understood as yet in the clinical setting. 
 
3.6.6 Clinical trials 
Scientific evidence on the clinical safety and efficacy of herbal preparations is still not sufficient. 
Numerous case reports on considerable use of herbal products are indicative for their 
effectiveness. The only option for the integration of traditional medicines into conventional 
medicine is to perform sound clinical trials (Zeng et al., 2015; Sahebkar et al., 2016; 
Schwinghackl et al., 2016; Tomé-Carneiro and Visioli, 2016). Herbal products should fulfill the 
criteria of evidence-based medicine just like synthetic chemical drugs too, in order to gain full 
recognition in conventional medicine. Therefore, placebo-controlled, double-blind and 
randomized clinical trials are required.  
Quality control is of utmost importance, actually everywhere in medicine, not only in traditional 
medicine in general or specifically phytotherapy. There have been considerable efforts during the 
past years to improve the quality of herbal preparations (Efferth, 2011; Efferth and Greten, 
2012c; 2012d; Booker et al., 2016; Singh et al., 2017; Liao et al., 2018). Other forms of 
traditional medicine such as acupuncture, massage, tuina massage, tai chi chuan etc. may not be 
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as easy accessible to quality control measures as phytotherapy. The relatedness of scientific 
methods to investigate natural products and synthetic drugs facilitate to generate high quality 
standards in both fields. However, even if the preclinical scientific understanding of these non-
pharmacological techniques of traditional medicine might be more difficult, the clinical efficacy 
can be monitored in a comparable way as other techniques of conventional medicine too. It is 
crucial to perform clinical phase I-III trials to demonstrate the clinical efficacy of non-
pharmacological forms of traditional medicine. Clinical trials will not only unravel the clinical 
efficacy of these methods themselves, but also the skills of those health professionals, who 
perform them (e.g., acupuncturists, masseur etc.). There have been several examples in the 
literature of randomized double blind clinical trials that have been performed according to the 
state of the art (Maimer et al., 2013; Sousa et al., 2015; Mayer-Hamme et al., 2018). Scholars 
working in non-pharmacological fields of traditional medicine should be encouraged to perform 
clinical trials and if adequate performance faces difficulties, novel adequate methods for clinical 
trials should be developed. This represents an important area of research that has to be developed 
in the yards to come.   
 
3.6.7 Phytovigilance 
As precise prescribing guidelines for self-prescribed herbal products are missing, the introduction 
of phytovigilance guidelines is justified to minimize the risk of herb-induced toxicity. Once 
evidence-based traditional medicines enter the market after the performance of clinical trials, 
pharmacovigilance studies should monitor adverse effects (Shaw et al., 2012; Zhang et al., 2012). 
Self-medication-induced morbidity can largely be avoided by proper documentation of the intake 
of herbal medicines in the patients’ personal medical. The relevance of this issue has been 
previously illustrated (Jaski et al., 2000). The authors surveyed primary care internists and family 
practitioners from the American Medical Association Physician Masterfile regarding their 
patients’ use of prescription drugs, OTC products, nutritional supplements, and herbal treatments.  
Almost all among the 655 responders reported reviewing prescription medications prior to 
prescribing a new therapy (99.8%), but only 86% reported simultaneous OTC product use of their 
patients. Less than half of the physicians reported the use of nutritional supplements or herbal 
products among their patients before prescribing a new therapy. These alarming results 
demonstrated that the use of non-prescription substances is not routinely documented in primary 
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care practice. Physicians should routinely ask patients about their use of dietary supplements and 
OTC products prior to starting treatment with prescribed drugs. There are still scant guidelines to 
assess safe self-administration of conventional and herbal medication (Mitty and Flores, 2007). 
 
3.6.8 Educational programs, databases and information centers 
As a matter of fact, most traditional uses of medicinal plants have not been sufficiently recorded 
to be available for a broad audience. It is reasonable to fear the loss of knowledge on medicinal 
plants for several reasons, e.g. destruction of habitats, disinterest of younger generations in 
practices handed down by older generations. The conversion of oral knowledge from shamans 
and indigenous healers to written documents will not only prevent the distinction of herbalistic 
knowledge, but will also foster the development of rational and scientifically based concepts for 
education and training at universities.  
There are several options to save knowledge on the use of traditional medicine for future 
generations. One such possibility is the generation of electronic database. An example is the 
Databank of Turkish Folk Medicine (Yesilada and Sezik, 2003). Furthermore, regional education 
centers may provide courses for further and continuing education of traditional practitioners such 
as the Bezmialem Center for Education, Research and Practice in Phytotherapy, which is the first 
phytotherapy center approved by the Council of Higher Education in Turkey. Finally, academic 
degrees from universities represent the most sophisticated from of formal education in traditional 
medicine. Indeed, several Bachelor programs have been established in the past years. An example 
is the B.Sc. Herbal Medicine degree program at the Kwame Nkrumah University of Science and 
technology (KNUST) in Ghana. This is a four-year program and graduates are licensed by the 
Traditional and Alternative Council of Ghana as herbal medicine practitioners (Aziato and 
Antwillo, 2016). 
In the United Kingdom, the University of East London, the Middlesex University, the 
University of Central Lancashire, the University of Westminster, the University of Lincoln, and 
the Napier University in Edinburgh offer B.Sc. degree programs in herbal medicines (Elumalai 
and Eswariah, 2012).  
At the patient side, self-administration of medication implies that the consumers are 
cognitively competent to manage their health care. However, this cannot always be guaranteed. 
Therefore, health care professionals (physicians, pharmacists, nurses, midwifes etc.) have the 
responsibility assessing the self-care ability of their patients (Glisson and Walker, 2010). To 
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fulfill this requirement, pharmaceutical databases are available with relevant information on drug 
action, adverse effects and toxicities as well as herb-drug interactions, e.g. the ABDA database of 
the German Institute for Medical Documentation and Information 
(http://www.dimdi.de/static/de/amg/abda/index.htm). With increasing popularity of 
complementary therapies, measures should be taken to provide reliable information to health 
professionals and patients alike (Tiran, 2006).  
Information centers for consumers and general practitioners represent a promising tool to 
meet the demand among patients for counseling and providing evidence-based information on 
toxicity risks. An example is “MotherSafe”, which has been established at the Royal Hospital for 
Women (Randwick NSW, Australia) to inform women on teratogenic exposures during 
pregnancy and lactation (Lim et al., 2009). 
 
4 Conclusions and perspectives  
The commercial misuse of indigenous knowledge on medicinal plants by some multinational 
companies culminated in efforts to ban biopiracy practices. While the Nagoya protocol was 
launched by the United Nations to regulate fair benefit-sharing at the legislative level, the 
momentum of this international development should be taken up by academia, where monetary 
and commercial aspects are not that much in the foreground. The valuable knowledge of 
traditional medicine represents and exquisite starting point for the realization of a One-World 
Medicine, whose concept is to integrate the best conceptual elements of conventional medicine 
CAM and traditional medicines to secure affordable primary health care for those patients in 
developing countries, who have no access to the expensive hi-tech medicine of the Western 
World. To have safe and efficient medications at hand, a number of measures have to be realized 
to improve traditional medicines, including  
 Performance of pharmacological mode-of-action analyses to clarify molecular and 
cellular mechanisms. It is advisable to use novel state-of-the art methods and high-
tech approaches to gain reputation also in the scientific community outside of 
medicinal herb research. 
 Quality control of herbal products by controlled cultivation and harvesting of 
medicinal plants, standardization of herbal products by phytochemical analyses, and 
safety control to avoid toxic contaminations and adulterations. 
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 Conduction of placebo-controlled, randomized, and double-blind clinical trials to 
provide convincing evidence for the safety and efficacy of herbal products. 
 Formal education of phytotherapists. Production and trade with herbal products should 
be licensed by the national governments. 
The establishment of primary health care infrastructure represents a main goal of all 
governments all over the world. Therefore, One-World Medicine approaches should rather be 
initiated and realized by governmental authorities than by the industry. Appropriate control 
organs should monitor the implementation of the processes to avoid biopiracy, corruption and 
any other kind of misuse.  
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